

## Product datasheet for **TL313966V**

### Factor H (CFH) Human shRNA Lentiviral Particle (Locus ID 3075)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Factor H (CFH) Human shRNA Lentiviral Particle (Locus ID 3075)
Locus ID:	3075
Synonyms:	AHUS1; AMBP1; ARMD4; ARMS1; CFHL3; FH; FHL1; HF; HF1; HF2; HUS
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CFH - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_000186</a> , <a href="#">NM_001014975</a> , <a href="#">NM_000186.1</a> , <a href="#">NM_000186.2</a> , <a href="#">NM_000186.3</a> , <a href="#">NM_001014975.1</a> , <a href="#">NM_001014975.2</a> , <a href="#">BC012610</a> , <a href="#">BC037285</a> , <a href="#">BC073982</a> , <a href="#">BC110643</a> , <a href="#">BC142699</a> , <a href="#">BM842566</a> , <a href="#">NM_000186.4</a>
UniProt ID:	<a href="#">P08603</a>
Summary:	This gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Oct 2011]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).